86 results about "Antigen binding site" patented technology

The present invention relates to: a receptor tyrosine kinase like orphan receptor 1 (ROR 1) antibody or an antigen-binding fragment thereof; a nucleic acid encoding same; a recombinant expression vector carrying the nucleic acid; a host cell transinfected with the recombinant expression vector; a method for preparing the antibody or the antigen-binding fragment thereof; a bi- or multi-specific antibody bearing the antibody or the antigen-binding fragment thereof; an immune cell-engaging bi- or multi-specific antibody; an antibody-drug conjugate (ADC) in which the antibody or the antigen-binding fragment thereof is bound to a drug; a chimeric antigen receptor (CAR) containing the scFv of the antibody as an antigen-binding site of an extracellular domain; an immune cell having the chimeric antigen receptor introduced thereinto; a composition for combination therapy including the antibody or the antigen-binding fragment thereof; a composition for preventing or treating cancer; and a method for preventing or treating cancer.

The application relates to specific binding members that bind OX40. The specific binding members comprise an OX40 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.

Provided herein are trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and / or trivalent binding proteins and uses of such binding proteins.

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Provided herein are compositions comprising trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and / or trivalent binding proteins and uses of such binding proteins for the treatment and / or prevention of HIV / AIDS.

The invention relates to a small molecule detection method. The method comprises the following steps: forming a multi-component compound containing'a first compound antibody-small molecules / small molecule binding partner compound-a second compound antibody ', and detecting the small molecules in a sample by detecting the multi-component compound, the micromolecule binding partner can be specifically bound with micromolecules, has at least two antigen binding sites, and can be bound with at least two micromolecules to obtain the micromolecule / micromolecule binding partner compound. And forming at least two new conformational epitopes different from the small molecule in the free state and the small molecule binding partner in the free state; each of the first complex antibody and the second complex antibody specifically binds to at least one new conformational epitope, and neither the first complex antibody nor the second complex antibody is an antibody of the small molecule antigen nor a specific antibody of the small molecule binding partner.

Provided herein are trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and / or trivalent binding proteins and uses of such binding proteins.

Disclosed are novel compounds comprising two antigen binding sites and a tetramerization site, wherein the antigen binding sites are selected from native binding sites. The novel compounds have improved manufacturability, stability, and solubility compared to similar compounds based on scFv binding sites, such that the disclosed compounds become significantly better candidates for active ingredients in pharmaceutical compositions.

Methods of treating coagulopathy using a bispecific antibody comprising (i) a first antigen-binding site capable of binding Factor Vll(a), and (ii) a second antigen-binding site capable of binding TREM-like Transcript 1 (TLT-1).

The invention relates to the technical field of biology, and aims to provide a monoclonal antibody 3E1 for resisting PGPV envelope protein and an application method of the monoclonal antibody 3E1. A heavy chain and a light chain of the monoclonal antibody respectively have three CDR subregions forming antigen binding sites, amino acid sequences of CDR1, CDR2 and CDR3 in a heavy chain variable region are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and amino acid sequences of CDR1, CDR2 and CDR3 in a light chain variable region are respectively shown as SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The monoclonal antibody 3E1 provided by the invention is high in affinity, strong in immunocompetence and good in specificity and uniformity, and has the advantages of high stability, high activity, strong affinity and the like; the monoclonal antibody is high in sensitivity and strong in specificity, and can be used for a PGPV diagnostic kit; a new technical support can be provided for rapid detection of the PGPV antibody, and the method has important significance in promoting healthy development of the pigeon industry and preventing, controlling and purifying PGPV epidemic situations.

The invention relates to the technical field of biology, in particular to a human CD4 and TGF-beta1 / 2 / 3 combined bispecific antibody which at least comprises a first protein functional area, and the first protein functional area comprises a first antigen binding site targeting CD4; and the second protein functional region comprises a second antigen binding site targeting TGF (Transforming Growth Factor)-beta 1 / 2 / 3. The bispecific antibody disclosed by the invention can be well and specifically combined with CD4 and specifically combined to helper T cells; meanwhile, the bispecific antibody can be combined with TGF beta 1, so that Th1 cell mediated cellular immunity is activated, TGF beta 2 and TGF beta 3 are neutralized, and the bispecific antibody has the effect of preparing the medicine for preventing and treating bacterial infectious diseases.

Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein:D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein:A is selected fromR1, R2 and R3 is H, ORa, OCORa, OCOORa, alkyl, alkenyl, alkynyl, etc; R3′ is, CORa, COORa, CONRaRb, etc; each of R4 to R10 and R12 is alkyl, alkenyl or alkynyl; R11 is H, CORa, COORa, alkyl, alkenyl or alkynyl, or R11 and R12+N+C atoms to which they are attached may form a heterocyclic group; each of R13 and R14 is H, CORa, COORa, alkyl, alkenyl or alkynyl; each Ra and Rb is H, alkyl, alkenyl, alkynyl, etc.;each dotted line represents an optional additional bond;X is an extending group; AA is an amino acid unit; L is a linker group; w is 0 to 12; b is 0 or 1; Ab is a moiety comprising at least one antigen binding site, and n is the ratio of the group [D-(X)b-(AA)w-(L)-] to the moiety comprising at least one antigen binding site and is in the range from 1 to 20, are useful in the treatment of cancer.

The invention relates to bispecific antigen binding proteins (ABP), such as bispecific antibodies, that bind with a first antigen binding site to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA). The bispecific ABP of the invention bind with a second antigen binding site to immune checkpoint (molecules) such as PD-1 or PD-L1. The bispecific ABP of the invention can also inhibit the interaction between LILRB1 and / or LILRB2 and a natural ligand of ULRB receptors (e.g. interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. Bispecific molecules combining LILRB1 / 2 antagonism with inhibition of immune checkpoints, such as the inhibition of the PD-1 / PD-L1 axis, is specifically useful in the treatment of proliferative disorders. Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and / or methods for treating infective- and / or proliferative diseases, using an LILRB1 and / or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and / or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods.

Disclosed herein are methods of treating autoimmune, allergic, and / or inflammatory diseases in a subject in need thereof, comprising administering a therapeutic agent comprising one or more antigen-binding sites on a cell involved in the autoimmune, allergic, and / or inflammatory diseases and depleting the cell.

The disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site. The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.

The present invention relates to radiolabeled molecules and related precursor molecules for the detection of immune cells expressing receptors comprising an antigen binding site and a signaling domain for binding to a P2X7 receptor of a dysfunction.

The present application relates to antibody molecules that bind both PD-L1 and CD137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.

Novel compounds are disclosed that contain two antigen-binding sites and a tetramerization site, where the antigen-binding sites are selected from naturally occurring binding sites. The novel compounds have improved manufacturability, stability, and solubility compared to similar compounds based on scFv binding sites, making the disclosed compounds much better candidates for active ingredients in pharmaceutical compositions.

The problem to be solved by the present invention is to provide more and better options for treating any solid tumor with high frequency microsatellite instability (high frequency MSI or MSI-H) alterations, cervical cancer, endometrial cancer, lung cancer, brain cancer and breast cancer.SOLUTION: The present invention relates to multispecific antibodies comprising an antigen binding site that binds an extracellular part of CD137 and an antigen binding site that binds an extracellular part of a second membrane protem for use in a method of treatment of cancers in a subject in need thereof. The invention further relates to such multispecific antibodies, as well as methods and other aspects related thereto.SELECTED DRAWING: None

To provide a binding molecule including two polypeptide chains, where the peptide chain includes a modification EHD2 domain which enables heterodimer only, by which homodimer is prevented, a nucleic acid encoding such a binding molecule, and use thereof in treatment.SOLUTION: A binding molecule includes a first polypeptide chain including a first binding domain (BD1), and a first modification EHD2 domain and a second polypeptide chain including a second binding domain (BD2) and a second modification EHD2 domain, where amino acid sequences of EHD2-1 and EHD2-2 are different from each other, each of which is selected from an amino acid sequence which has at least 70% amino acid identity to a specific amino acid sequence, and does not have Cys at position 14 or a position 102, and BD1 and BD2 form an antigen-binding site together, wherein, EHD2-1 and EHD2-2 are covalently bonded to each other.SELECTED DRAWING: None

The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen¬binding fragments and a modified Fc region to facilitate heterodimer formation. In one embodiment, the bispecific antibodies further comprise protease cleavage sites and / or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and / or cross-reactive binding to CDS on cells from different species.

The invention relates to a bispecific antibody or an antigen-binding fragment thereof comprising a first antigen binding site that can bind to TIGIT and a second antigen binding site that can bind to 4-1BB; pharmaceutical compositions comprising such bispecific antibodies and uses thereof. In particular, the antibody or the antigen-binding fragment thereof or the bispecific antibody or an antigen-binding fragment thereof can cause activation of T cells and then it can effectively prevent or treat the cancer.

The application relates to specific binding members that bind OX40. The specific binding members comprise an OX40 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.

Anti-CD47 / anti-TIGIT bispecific antibody, a preparation method thereof and application thereof. The bispecific antibody comprises: (a) a first antigen binding part, comprising heavy chain variable region (VH) and light chain variable region (VL), VH and VL forming an antigen binding site that specifically binds to CD47; and (b) a second antigen binding part, comprising a single domain antibody (sdAb) that specifically binds to TIGIT, wherein the first antigen binding part and the second antigen binding part are fused with each other. The bispecific antibody can block two modes of tumor immune escape at the same time, thus having a good effect in tumor immunotherapy.

The present invention improves an effect of killing or an effect of inhibiting the growth of cancer cells. The present invention comprises: a binding domain that includes a first antigen-binding site that binds to a cancer cell and a second antigen-binding site that binds to a T cell; a cleavable sequence that is linked to the binding domain; and a masking moiety that is linked to the N-terminus of a single-chain antibody via the cleavable sequence when the binding domain is composed of the single-chain antibody, and that is linked to the C-terminus of each light chain via the cleavable sequence when the binding domain is composed of heavy chains and light chains. In a state in which the cleavable sequence is cleaved, the masking moiety functions as an agonist of a co-stimulatory molecule for the T cell or an antagonist of a co-inhibitory molecule for the T cell.

The invention relates to a bispecific antibody or an antigen-binding fragment thereof comprising a first antigen binding site that can bind to TIGIT and a second antigen binding site that can bind to 4-1BB; pharmaceutical compositions comprising such bispecific antibodies and uses thereof. In particular, the antibody or the antigen-binding fragment thereof or the bispecific antibody or an antigen-binding fragment thereof can cause activation of T cells and then it can effectively prevent or treat the cancer.

The present disclosure provides trispecific and / or trivalent binding proteins that comprise four polypeptide chains forming three antigen-binding sites, wherein the three antigen-binding sites specifically bind one or more target proteins, wherein a first pair of the polypeptide chains forming the binding protein have dual variable domains with a cross orientation, and wherein a second pair of the polypeptide chains have a single variable domain forming a single antigen-binding site. In some embodiments, the binding protein comprises a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. The present disclosure also relates to methods for preparing trispecific and / or trivalent binding proteins and uses of such binding proteins.

The application belongs to the technical field of bioengineering, and particularly relates to a monoclonal antibody against canine IFN-alpha and application thereof. The monoclonal antibody comprises a monoclonal antibody 1C1 or an antigen binding site thereof and a monoclonal antibody 2A4 or an antigen binding site thereof, and the monoclonal antibody and the antibody combination thereof are carefully screened and optimized, can be used for detection of canine interferon, and have extremely high specificity and sensitivity. An ELISA kit developed by the antibody combination not only simplifies a detection process, but also improves detection efficiency. The capture antibody and the detection antibody in the kit can synergistically act, can realize high-precision detection of the canine interferon, are not only high in detection sensitivity, but also excellent in specificity, effectively avoid interference of non-specific reactions. The technical breakthrough exhibits broad development potential and practical application prospect, and provides a powerful tool for canine health monitoring, disease diagnosis and related research.

The present invention addresses the problem of providing a novel fusion protein that can efficiently deliver a drug such as an oligonucleotide therapeutic or a small molecule drug to a target site and can more effectively suppress side effects (systemic exposure to the drug). The present invention relates to a fusion protein that includes an antibody domain (A) that has at least one antigen binding site, a stabilization domain (B) that has an α-helix structure and is linked to the antibody domain (A) directly or by a linker, and a membrane adhesion domain (C) that is linked to the stabilization domain (B) directly or by a linker. The present invention also relates to: a conjugate that is formed by bonding the fusion protein and a particle that has an organic membrane that includes a lipid that includes an amphoteric ion; and a pharmaceutical composition that includes the conjugate.

To provide a technique relating to the field of antibodies, in particular a technique relating to the field of therapeutic (human) antibodies for treatment of ErbB-2 / ErbB-3 positive cells, more in particular treatment of cells including an NRG1 fusion gene including at least a portion of the NRG1-gene fused to a sequence derived from a different chromosomal location.SOLUTION: The present invention provides a bispecific antibody that comprises a first antigen-binding site that can bind to an extracellular part of ErbB-2 and a second antigen-binding site that can bind to an extracellular part of ErbB-3 for use in treatment of an individual that has ErbB-2 and ErbB-3 positive cells, the cell including an NRG1 fusion gene including at least a portion of the NRG1 gene fused to a sequence derived from a different chromosomal location.SELECTED DRAWING: None